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Clostridium difficile infection is a toxin-mediated disease of the colon. C. difficile virulence is primarily
attributed to the production of toxin A and toxin B; thus this study was aimed to investigate the effect
of a range of natural products on the production and activity of C. difficile toxins in vitro. Twenty-two
natural products were investigated against four C. difficile strains. The activity of products against
toxins was determined using Vero and HT-29 cells cytotoxicity and neutral red uptake assays. The
indirect effect of products on toxin-mediated cytotoxicity was determined using the same cell lines.
The effect of seven products on toxin production by C. difficile was determined using ELISA. Zingerone
(0.3 mg/ml) protected both cell lines from C. difficile cytopathic effects, confirmed by the neutral red
uptake assay (P < 0.05). Three Leptospermum honeys (4% w/v), fresh onion bulb extract (12.5% v/v) and
trans-cinnamaldehyde (0.005% v/v) all reduced toxin production and activity significantly (P ≤ 0.023).
Garlic clove powder (4.7 mg/ml) only reduced toxin activity (P ≤ 0.047). Overall, several natural products
had activity against C. difficile toxins in vitro encouraging further investigation against C. difficile toxins
in vivo.
Clostridium difficile infection (CDI) is one of the most important healthcare-associated infections worldwide and
a major cause of morbidity and mortality in both the hospital and community settings1. Typically, CDI occurs
following the disruption of normal enteric flora, usually post-antimicrobial exposure, leading to the proliferation
and germination of C. difficile spores into vegetative cells, resulting in toxin production in the intestine2. Toxin A
(TcdA, 308 kiloDaltons, kDa) and toxin B (TcdB, 270 kDa) belong to the large clostridial glucosylating family of
toxins and are the major virulence factors of this species3. Despite similar enzymatic activities, TcdA and TcdB
have different cellular receptors, in vivo potency and immunological response, and recent studies of isogenic toxin
mutants in hamster and piglet models provided convincing evidence that toxin B alone is essential for CDI3,4.
Secretion of these potent toxins within the gastrointestinal tract causes actin disassembly, enterocyte apoptosis,
the breakdown of epithelial tight junctions and an overall loss of epithelial integrity3. This pathophysiological cascade results in extensive colonic inflammation, epithelial tissue damage and a rapid loss of fluid into the intestinal
lumen, manifesting as characteristic watery diarrhoea but may also develop into fatal sequelae including pseudomembranous and fulminant colitis3,4. In vitro cellular apoptosis is seen clearly in the characteristic “cell rounding” phenotype or cytopathic effect (CPE). Some C. difficile lineages, most notably the hypervirulent NAP1/027
epidemic strain, also produce a third toxin known as binary toxin (CDT), however, there is still little known about
the role of this toxin in virulence5.
For the last three decades, CDI has been managed with the conventional antimicrobials metronidazole (for
mild to moderate CDI) and vancomycin (for severe CDI)6. Despite retaining good in vitro efficacy against C.
difficile, several issues remain surrounding the use of these agents. Increasingly, they are associated with unacceptably high rates of CDI recurrence, reduced efficacy in vitro and minimal inhibitory concentration (MIC)
creep, particularly with metronidazole, and with vancomycin, there is a risk of selection for acquired glycopeptide
resistance in Gram-positive pathogens7–9. Fidaxomicin became available for treatment of CDI in 2011. It has a
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narrower spectrum of activity compared to vancomycin and metronidazole, and thus may have has less impact on
gut microbiota. However, its high cost compared to either metronidazole or vancomycin has restricted its use10.
Medicinal plants remain the primary source of treatment for several diseases in rural areas of many developing countries11. Plant-derived compounds are considered by some consumers as a safer, less toxic and more
environmentally-friendly option compared to conventional therapies. They are typically multi-component in
nature and the components contain different functional groups. As such, their antimicrobial activity often relates
to multiple mechanisms; hence, unlike conventional antimicrobials, organisms are less likely to develop resistance12. We have shown recently that several natural products have antimicrobial activity against C. difficile in
vitro13. Given that CDI is a toxin-mediated disease, the purpose of the present study was to investigate the effect
of those previously tested natural products, and corresponding pure substances, on toxin production and activity
in C. difficile in vitro. The anti-toxin activity of natural products and their impact on toxin-mediated cytotoxicity
were assessed using tissue culture and cytotoxicity assays. ELISA was performed to determine the effect of these
products on the production of C. difficile toxins.

Results

Antimicrobial susceptibility assay. The MICs of natural products (Table 1)14 and antimicrobial controls
for the four strains of C. difficile have previously been published13 and are shown in Table S1. The only exception
was the two extra Leptospermum honeys A and B as listed in Table 1. Both honeys A and B showed an MIC of 16%
v/v, which was two-fold lower than previously tested Leptospermum honey C.
Toxin protection assay.

The supernatants from the three toxigenic strains demonstrated CPE in both Vero
and HT-29 cells. However, only minor CPE was observed with C. difficile ATCC 43598 and HT-29 cells. This
was shown as cell rounding, membrane blebbing and loss of adhesion. The toxin titres for each of the three toxigenic C. difficile strains causing approximately 90% CPE were determined over three independent experiments.
A modal toxin titre was selected for each strain (Table 2). The highest concentrations of each antimicrobial agent
showing no effect on cells are shown in Table S2. In addition, the pH of the growth medium with and without the
addition of each compound was measured to determine whether there was a deviation in pH that could interfere
in the assay. No significant deviation was observed. When culture filtrates were incubated for 2 h with antimicrobial agents, only zingerone protected Vero cells against any cytotoxic effect visually. This was confirmed by a
neutral red uptake assay (P ≤ 0.007) (Figs 1, S1 and S2). Also, when Vero cells were pre-incubated with zingerone
for 2 h prior to the addition of culture filtrates, a similar protective effect was observed. However, when zingerone
and culture filtrates were transferred to the wells containing Vero cell monolayers together, and with no prior
incubation, no protection was observed. Zingerone showed a similar protective effect against toxin activity on
HT-29 cell monolayers (Figs 2, 3 and S3).

Indirect effect of natural products on toxin-mediated cytotoxicity.

The effect of all products on
toxin-mediated cytotoxicity on Vero cells was examined for C. difficile NCTC 13366 and R44116 (Table S3), and
products showing a reduction in CPE were further tested against C. difficile ATCC 43598. Exposure to six of the
22 natural products significantly reduced cytotoxicity with Vero cells compared to untreated culture filtrate of the
three toxigenic strains of C. difficile (P ≤ 0.047) (Fig. 4). The cytotoxicity titres for C. difficile cultures incubated
for 48 h with 0.5 × and 0.25 × MICs of fresh onion bulb extract, garlic clove powder, trans-cinnamaldehyde and
the three Leptospermum honeys were reduced by ≥70% compared to the untreated controls. Similar findings were
observed for HT-29 cells (P ≤ 0.001), with the exception of garlic powder at 0.25 × MIC which did not show any
reduction in CPE.

Effect of treatments on C. difficile toxin production. Seven of the 22 products that showed activity in
either direct or indirect toxin activity assays were selected to determine their effect on toxin production by the
three toxigenic C. difficile strains using ELISA. Toxin production for C. difficile strains in the presence of treatments relative to untreated cultures is shown in Fig. 5. Fresh onion bulb extract, trans-cinnamaldehyde and the
three Leptospermum honeys significantly reduced toxin production by all three toxigenic strains compared to
the untreated controls (P < 0.001). At 48 h, these products inhibited toxin production by ≥40% in the toxigenic
strains.

Discussion

Toxins are the main virulence factors of C. difficile, which initiates gastrointestinal disease by causing inflammation and mucosal damage in the intestine15. Therefore, investigating toxin-active therapeutic agents with low risk
of developing antimicrobial resistance is of great interest in either treating or preventing CDI8. In this study, the
effect of a range of natural products, and the corresponding pure substance, on toxin activity of C. difficile was
examined using Vero and HT-29 cells. Similar results were observed with both cell lines. The toxin protection
study showed that the ginger component zingerone protected cells against the effect of C. difficile toxin. In this
assay, protection against toxin activity was observed when culture filtrates and zingerone were incubated together
for 2 h prior to being added to the cells, as well as when the cells were pre-incubated with zingerone prior to addition of culture filtrates. However, no significant protection was observed when toxin filtrates and zingerone were
added simultaneously to wells containing either Vero or HT-29 cells. Hence, it is likely that zingerone provides
protection against the action of C. difficile toxin by blocking either the toxin-binding sites on toxin molecules
or the host cell receptors. In an earlier study by Chen et al., the effect of ginger and its bioactive components on
inhibition of enterotoxigenic Escherichia coli heat-labile enterotoxin (LT)-induced diarrhea in mice was investigated. Ginger extract inhibited fluid accumulation in the ileal loops of mice by blocking the binding of LT to
GM1 cell-surface receptor. Further investigation of biologically-active components showed that zingerone was the
active constituent responsible for the anti-diarrhoeal effect of ginger16.
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Product

Concentration

Ingredient information

Supplier

Raw products
Fresh garlic bulb

1 ml/ml

None

—

Fresh onion bulb

1 ml/ml

None

—

Fresh ginger rhizome

1 ml/ml

None

—

Leptospermum honey
(MGO 514+) (A)

100% pure Manuka honey

None

Barnes Naturals, Richlands, QLD,
Australia

Leptospermum honey
(MGO 263+) (B)

100% pure Manuka honey

None

Barnes Naturals

Leptospermum honey
(MGO 263+) (C)

100% pure Manuka honey

None

Barnes Naturals

Garlic clove powder

1 mg/mg

None

Spencers, Fremantle, WA, Australia

Ginger rhizome powder

1 mg/mg

None

Spencers

Cinnamon root powder

1 mg/mg

None

Spencers

Turmeric root powder

1 mg/mg_

None

Spencers

Garlic tablet

Garlic (Allium sativum) extract
equivalent to dry bulb 10,000 mg

No added yeast, starch, gluten, lactose, sugar, artificial colours
or flavours, artificial sweeteners or preservatives, dairy
products or animal-derived products.

Nature’s Own, Virginia, QLD, Australia

Ginger tablet

1000 mg

No added yeast, starch, gluten, lactose, sugar, artificial colours
or flavours, artificial sweeteners or preservatives, dairy
products or animal-derived products.

Nature’s Own

Cinnamon tablet

Cinnamon (Cinnamomum cassia) stem No added lactose, egg, gluten, soy, yeast, artificial colours and
bark inner powder 1000 mg
artificial flavours.

Turmeric tablet

1000 mg

Turmeric powder 77%, cellulose microcrystalline,
povidone, silica colloidal anhydrous, magnesium stearate,
croscarmelloose sodium.

Nature’s Way, Warriewood, NSW,
Australia

Herbal extract equivalent to Cynara
scolymus fresh leaf 60000 mg

No added lactose, starch, added sugars and salt, artificial
colourings and flavourings or preservatives.

Nature’s Sunshine, Baulkham hills, NSW,
Australia

Coconut oil capsule

100% coconut oil

Capsule shell (gelatin, glycerol, water)

Nature’s Way

Peppermint oil

100% pure, Mentha X piperita leaf
1 ml/ml

None

Oil Garden, Springvale, VIC, Australia

Aloe vera gel

99% pure Aloe Barbadensis

Allantoin (found in Comfrey root), carbomer, disodium
edetate, sodium hydroxyl methylglycinate, grapefruit seed
extract

Plunkett’s, Warriewood, NSW, Australia

180 mg allicin extract (garlic bulb)

Vegetarian capsule (hypromellose, water), maltodextrin, gum
acacia, Made without corn, wheat, gluten, yeast, soy, sugar,
dairy, artificial colors or flavors

Vcaps, Chicago, IL, USA.

Processed products

Swisse, Collingwood, VIC, Australia

Processed products
Artichoke capsule

Pure compounds
Allicin
trans-Cinnamaldehyde

Purity >98.5%

None

Sigma Aldrich, Saint Louis, MO, USA

Menthol

Purity >98.5%

None

Sigma Aldrich

Zingerone

Purity >96%

None

Sigma Aldrich

Table 1. Range of natural products used in this study. MGO, methylglyoxal. (Table extracted from Roshan et al.
2018).

With the indirect toxin-mediated cytotoxicity assay and ELISAs, several products such as the three
Leptospermum honeys, fresh onion bulb extract and trans-cinnamaldehyde at 0.5 and 0.25 × MIC, showed a
reduction in both toxin production and activity. Garlic clove powder at 0.5 and 0.25 × MIC showed a reduction in toxin activity with Vero cells and at 0.5 × MIC with HT-29 cells. Also, the ELISAs did not indicate any
significant decrease in toxin production with garlic powder compared to the untreated controls. Previously,
trans-cinnamaldehyde (0.38 mM; 0.05 mg/mL) reduced both C. difficile toxin production and activity in vitro17.
In a study by Upadhyay et al., trans-cinnamaldehyde (0.5 mM) down-regulated hly and prfA genes coding for
toxin production and a transcriptional regulator in Listeria monocytogenes18. The activity of several antimicrobials
such as fidaxomicin, its major metabolite (OP-1118), metronidazole and vancomycin against C. difficile toxin has
been investigated previously19. That study showed that both fidaxomicin and OP-1118 at 0.25 × MIC inhibited
toxin production by ≥60% following 1 week of culture. Also, a near complete inhibition of toxin gene expression
was observed with both fidaxomicin and OP-1118 at 2 and 2.5 × MIC, respectively. No inhibitory effect on C.
difficile toxin production or gene expression was reported for either metronidazole or vancomycin19. In our study,
fidaxomicin was used as an antimicrobial control and showed a reduction in both C. difficile toxin production
and activity.
Notwithstanding the protective effect of zingerone against C. difficile toxin observed in the toxin protection
assay, zingerone did not show any effect in either the indirect toxin-mediated cytotoxicity assay or toxin production assays. Theoretically, zingerone has a relatively rapid bactericidal action and its activity may degrade over
time, although there are no published literature to support this hypothesis. In indirect toxin-mediated cytotoxicity
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Modal toxin titre (range)
C. difficile strain

Vero cells

HT-29 cells

NCTC 13366

1:524,288 (1:524,288 – 1:2,097152)

1:262,144 (131,072-524,288)

R11446

1:8,192 (1:2,048 – 1:8,192)

1:8,192 (4,096-8,16,384)

ATCC 43598

1:512 (1:512 – 1:1,024)

1:8 (1:8-1:32)

Table 2. C. difficile toxin titre required to achieve 90% CPE on Vero and HT-29 cells after 24 h incubation at
37 °C with 5% CO2.
and toxin production assays, treatments were not exposed directly to the toxin and it would have had taken some
time for C. difficile to initiate toxin production. By the time the cells had started to produce toxin, the activity of
zingerone may have been minimal. Moreover, since gene expression for toxin production occurs during the late
log-phase, the addition of the compound during this stage could determine the effect of zingerone on toxin gene
expression. This will be studied in a series of experiments in the future.
Food-grade and plant-derived compounds are used commonly among people who practice self-health care10.
Many consumers turn to natural products assuming that natural is synonymous with safe. This concept is not
necessarily true as side effects are expected with some20. Some natural products such as trans-cinnamaldehyde are
toxic to humans if consumed in large quantities21. However, many natural products, including those used in this
study, have “generally recognised as safe” (GRAS) status with the US Food and Drug Administration. This means
that when consumed in moderate amounts they are unlikely to pose a health risk21. In addition, further studies on
the chemical composition of these products, as distinct from pure substances, will be of importance. Until such
studies are done, the results from investigations of “natural products’ should be interpreted with caution.

Conclusions

Overall, this study highlights the activity of a number of food-grade and plant-derived products against C. difficile toxins in vitro. These results suggest that several natural products may have the potential to be considered
as either alternative or complementary treatment options for CDI. Applying anti-virulence strategies such as
disruption of toxin production and toxin-mediated pathology in patients with CDI has the potential to be an
effective approach in either controlling or treating infection. However, further studies are required to investigate
the mechanistic basis for the anti-toxin activity observed as well as to determine their potential benefits in vivo.

Material and Methods
Bacterial strains.

The following four Clostridium difficile strains were used in this study: non-toxigenic C.
difficile ATCC 700057 (A−B−CDT−), C. difficile NCTC 13366 (PCR ribotype (RT) 027, A+B+CDT+), C. difficile
R11446 (RT 014, A+B+CDT−, clinical isolate) and C. difficile ATCC 43598 (RT 017, A−B+CDT−). Strains were
obtained from the School of Biomedical Sciences at The University of Western Australia and PathWest Laboratory
Medicine, WA.

Antimicrobial agents. Twenty-two natural products were selected for investigation based on historical evi-

dence, their current popularity, and feasibility (Table 1). The products were categorized into three broad groups;
raw products usually consumed as food, processed products taken as health supplements and the active pure
compounds found in these products. The raw products (n = 10) were purchased from a supermarket in Perth,
Western Australia (WA) (Table 1) while the Leptospermum honeys were kindly provided by Capilano Company,
Bayswater, WA. Processed and pure products (n = 12) were purchased from pharmacies and health food stores in
Perth, WA, or from the manufacturers (Table 1). The products were prepared for testing as previously described13.
Fidaxomicin and vancomycin were used as antimicrobial controls in susceptibility testing and fidaxomicin was
used as an effective-antimicrobial control in tissue culture and ELISA assays. Stock solutions of products in the
form of powder or oil were prepared in 20% dimethyl sulfoxide (DMSO). Further dilutions were performed in
sterile distilled water (SDW) for all products. Prior to testing, raw products were filtered through a 0.22 µm-pore
size Millipore filter to remove any microbial contamination, however, the processed products were not filtered as
they were assumed to have had gone through a sterilization process during manufacturing.

Determination of minimum inhibitory concentration (MIC).

Minimum inhibitory concentrations
(MIC) for natural products and comparator antimicrobial agents were determined by the broth microdilution
method as previously described13. Doubling dilutions of 20% DMSO were prepared and tested in parallel (solvent
control), and fidaxomicin and vancomycin were included as antibiotic controls. The previously determined MICs
for these products against the stationary phase C. difficile were used in this study.

Toxin protection assay. Tissue culture. The toxin protection assay was performed as described previously8

with slight modification. The Vero (African green monkey kidney) and HT-29 (human colon carcinoma) cells
were passaged in a 96-multiwell plate and incubated for 24 h prior to use. To prepare confluent monolayers, Vero
and HT-29 cells were dispensed into 96-well trays at 6 × 104 cells/well and 5 × 105 cells/well, respectively. Vero
cells were passaged and maintained in Dulbecco’s Modified Eagles Medium (DMEM). DMEM supplemented with
10% (DMEM-GM) and 2% foetal bovine serum (DMEM-MM) were used as growth and maintenance medium,
respectively. Both DMEM-GM and DMEM-MM also contained 200 µg/ml vancomycin and 100 µg/ml streptomycin sulfate. HT-29 was passaged and maintained as above, except that the medium also contained glucose (6 g/l).
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Figure 1. Protection from cytopathic effect on Vero cells using microscopy (C. difficile NCTC 13366 culture
filtrate and zingerone were incubated at 37 °C for 2 h prior to being added to Vero cell monolayers). (A) No
culture filtrate; (B) culture filtrate only; (C) zingerone (1.2 mg/ml); (D) zingerone (0.6 mg/ml); (E) zingerone
(0.3 mg/ml); Light microscopy ×40, Scale: 50 µm.

Figure 2. Protection from cytopathic effect on HT-29 cells using microscopy (C. difficile NCTC 13366 culture
filtrate and zingerone were incubated at 37 °C for 2 h prior to being added to HT-29 cell monolayers). (A) No
culture filtrate; (B) culture filtrate only; (C) zingerone (1.2 mg/ml); (D) zingerone (0.6 mg/ml); (E) zingerone
(0.3 mg/ml); Light microscopy ×40, Scale: 50 µm.

Figure 3. Cell viability determined by neutral red uptake assay. (Culture filtrates and treatments were incubated
2 h prior to being added to the cells); (A) Vero cells; (B) HT-29 cells; Statistical significance: *P < 0.05, **P < 0.01,
***P < 0.001 compared to culture filtrate control.

Culture filtrate preparation. C. difficile strains were cultured on blood agar for 48 h, from which suspensions
equivalent in turbidity to a 2 McFarland standard were prepared in 0.85% saline. A volume of 100 µl of each suspension was inoculated into a 10 ml pre-reduced brain heart infusion broth (BHIB). Following 5 h of anaerobic
incubation, the broth cultures were aseptically sealed and incubated for a further 5 days at 37 °C in a Thermocube
incubator (Bioline) with shaking at 120 revolutions per minute (rpm). After 5 days of incubation, cultures were
centrifuged at 4,000 × g for 5 min and the supernatant containing toxin was passed through a 0.22 µm-pore size
Millipore filter to remove cells and debris.
Toxin titration. Serial two-fold dilutions of culture filtrate in DMEM-MM were prepared with a total volume of
100 µl per well and were added to the cells. The 90% cytotoxicity titre was determined visually using an inverted
microscope (Olympus Corporation, Tokyo, Japan) at ×400 magnification. All titrations were performed three times.
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Figure 4. Indirect effect of treatments on C. difficile cytotoxicity on (A) Vero cells and (B) HT-29 cells.
Concentrations of agents used in the assay: Fresh onion bulb extract (25% and 12.5% v/v); Garlic clove powder
(4.7 and 2.3 mg/ml); Leptospermum honey (A), (B) and (C) (8% and 4% v/v); trans-Cinnamaldehyde (0.01%
and 0.005 v/v); Zingerone (4.7 and 2.3 mg/ml); Fidaxomicin (0.06 µg/ml). Statistical significance: ∆P < 0.05,
Ο
P < 0.01, *P < 0.001 compared to controls; *LH, Leptospermum honey; SDW, sterile distilled water; DMSO,
dimethyl sulfoxide.

Preparation of natural products. Natural products were prepared as described above. Serial two-fold dilutions of
natural products, fidaxomicin and DMSO were prepared in DMEM-MM and 100 µl volumes of each were added
to Vero cell monolayers. The highest concentrations showing no visible effect on cell monolayers after 24 h incubation was used in the subsequent assay.
Incubation of products and culture filtrates. The highest concentrations of all products with no visible effect on
cell monolayers, in addition to 2-fold and 4-fold lower concentrations, were used in this assay. Those products
that showed protection against toxin on Vero cells were also tested on HT-29 cells. Supernatants from the three
toxigenic C. difficile strains were diluted to 4-fold higher than the minimum dilution required to achieve 90% cell
rounding to account for the possible variation and dilution factor. The culture filtrates and products were both
diluted in DMEM-MM. To evaluate whether natural products reduced the activity of free toxin, diluted antimicrobial agents and supernatants were mixed at a ratio of 1:1 and incubated at 37 °C for 2 h. Aliquots of 100 µl of
1:1 antimicrobial agents: culture filtrates were added to 96-well microtiter plates containing Vero cell monolayers
and incubated for 24 h at 37 °C in a CO2 incubator (Thermo Fisher Scientific, Waltham, MA USA) containing 5%
CO2. Protection from CPE was evaluated with an inverted microscope and was verified with a neutral red uptake
assay (see below).
Culture filtrates from non-toxigenic C. difficile ATCC 700057 and the three other toxigenic strains without
the addition of antimicrobial agents were used as controls, with the three toxigenic strains showing a CPE but not
the non-toxigenic strain. The assay was repeated on three different occasions. If protection was achieved by any
of the products, they were further investigated to assess their likely mode of action, such as blocking the binding
sites or inactivating the toxin. To investigate whether that product blocked cell binding sites, the cell monolayers
were pre-incubated for 2 h with treatments at 2-fold higher than the desired concentrations at 37 °C with 5% CO2,
followed by the addition of an equivalent amount of C. difficile culture filtrate. Lastly, to evaluate whether protection occurred immediately or pre-incubation was required, diluted antimicrobial agents and culture filtrates
were mixed at a ratio of 1:1 and 100 µl of the mixture was immediately transferred to the wells containing cell
monolayers.

Neutral red uptake assay. A neutral red uptake assay was performed to determine cell viability and to
confirm the visual perception of protection from CPE21. Following the visual evaluation of results after 24 h of
incubation, the contents from each well were removed and a 100 µl aliquot of 40 µg/ml neutral red solution was
added. Plates were incubated for 3 h at 37 °C with 5% CO2, then washed with 150 µl of phosphate buffered saline
Scientific Reports |

(2018) 8:15735 | DOI:10.1038/s41598-018-33954-2

6

www.nature.com/scientificreports/

Figure 5. Effect of treatments on C. difficile toxin production. Concentrations of agents used in the assay:
Fresh onion bulb extract (25% and 12.5% v/v); Garlic clove powder (4.7 and 2.3 mg/ml); Leptospermum honey
(A,B) and (C) (8% and 4% v/v); trans-Cinnamaldehyde (0.01% and 0.005 v/v); Zingerone (4.7 and 2.3 mg/ml);
Fidaxomicin (0.06 µg/ml). Statistical significance: ∆P < 0.05, ΟP < 0.01, *P < 0.001 compared to controls; *LH,
Leptospermum honey; SDW, sterile distilled water; DMSO, dimethyl sulfoxide.

(PBS pH 7.3). To elute the stain, 150 µl of neutral red destain solution was added to each well and the plates were
placed on a shaker at 120 rpm for 10 min. The optical density of each well was measured at 540 nm using an
xMarkTM microplate spectrophotometer (Bio-Rad). Wells without cells served as blanks. The percentage of viable
cells in wells containing treated and untreated culture filtrates was calculated relative to the untreated control
cells, which were assumed to be 100% viable.

Indirect toxin-mediated cytotoxicity assay.

The indirect effect of all 22 products on the activity of C.
difficile toxins was determined using the Vero cell cytotoxicity assay as described previously22. Those products
showing any effect against toxin on Vero cells were further tested with HT-29 cells. Briefly, a bacterial suspension
of 1 × 106 cfu/ml was prepared for each strain in pre-reduced BHIB containing 0.5 × MIC and 0.25 × MIC of
treatments. The final volume for each bacterial suspension was 5 ml after addition of treatments. After incubating
the cultures for 48 h anaerobically at 35 °C, they were centrifuged at 4,000 g for 10 min and the supernatant filtered
through a 0.22 µm pore-size membrane filter. The culture filtrates were diluted 1:100 prior to being added to the
cell monolayer plates to reduce the gross effect of products on cells. The diluted culture filtrates were further
serially diluted 1:2 in 96-well microtiter plates containing cell monolayers using DMEM-MM. The plates were
incubated at 37 °C in 5% CO2 for 48 h and examined under an inverted microscope. The reciprocal of the highest
dilution causing 90% cell rounding was expressed as the cytotoxicity titre. All the products were tested against C.
difficile NCTC 13366 and C. difficile R11446 using Vero cells and those products showing a reduction in cytotoxicity titre were further tested against C. difficile ATCC 43598. Only C. difficile NCTC 13366 and C. difficile R11446
were used for the HT-29 cell line, as just a minor CPE was observed with C. difficile ATCC 43598 with those cells.
Fidaxomicin was used as a positive control (reducing CPE) and culture filtrate from C. difficile ATCC 700057 was
used as a negative control (showing no CPE) in this assay.

Effect of products on toxin production.

The amount of toxin in cultures grown in the presence of
0.5 × MIC and 0.25 × MIC of treatments showing activity in either toxin activity assays was determined relative
to the amount of toxin in control cultures (grown without antimicrobials) using the C. difficile TOX A/B IITM
ELISA kit (TechLab ). Also, fidaxomicin was included as an antimicrobial control. The culture supernatant from
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C. difficile strains was prepared and filtered as described earlier. The culture filtrates were diluted and tested according to the manufacturer’s instructions. The spectrophotometer was blanked against air at a wavelength of 620 nm
and the optical density (OD) was measured at 450 nm. Relative toxin production was expressed as a percentage of
OD450 for treated culture filtrates over OD450 of untreated culture filtrates.

Statistical analysis.

All assays were repeated at least three times. A modal value was determined for MIC
values obtained by the broth microdilution assay and for the cytotoxicity titres in the indirect cytotoxicity assay.
The mean and standard deviation (SD) were calculated for the percentage of viable cells in the neutral red uptake
assay and for toxin production in ELISA assays. Statistical differences between three or more sets of data were
analysed using GraphPad Prism v.7 software using one-way analysis of variance (ANOVA) and nonparametric technique, followed by Tukey’s multiple comparison post-test if the P value was significant. Moreover, the
Student’s 2-tailed t-test assuming unequal variance was used to determine whether there was a significant difference between two sets of data. Toxin titres in the indirect toxin study were converted to log2 values and titre
reciprocals that were lower than 100 were converted to a lower titre reciprocal of 50 to enable analysis. P values of
<0.05 were considered significant.
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